ClinicalTrials.gg
Active, not recruitingNCT05705349Updated Oct 5, 2026

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

A Phase 3 interventional study of DOR/ISL and BIC/FTC/TAF in HIV-1 Infection, sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 131 sites in 21 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
537
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a randomized, active-controlled, double-blind clinical study designed to evaluate the antiretroviral activity, safety, and tolerability of doravirine/islatravir (DOR/ISL [MK-8591A]) in treatment-naïve participants with human immunodeficiency virus type 1 (HIV-1) infection. It is hypothesized that DOR/ISL is non-inferior to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as assessed by the percentage of participants with HIV-1 ribonucleic acid (RNA) \<50 copies/mL at Week 48.

02

Conditions studied

  • HIV-1 Infection
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is -1 positive with plasma HIV-1 RNA ≥500 copies/mL at screening
  • Is naïve to antiretroviral therapy (ART) defined as having received no prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection
  • If female, is not a participant of (POCBP); or if a POCBP, is not pregnant or breastfeeding, and is willing to use an acceptable method or abstain from heterosexual intercourse for study duration

Exclusion criteria

Exclusion Criteria:

  • Has -2 infection
  • Has or other to any of the components of the study interventions as determined by the investigator
  • Has a diagnosis of an active AIDS-defining opportunistic infection within 30 days prior to screening
  • Has active infection (defined as hepatitis B surface antigen [HBsAg]-positive or HBV deoxyribonucleic acid [DNA]-positive).
  • Has chronic virus (HCV) infection (detectable HCV ribonucleic acid [RNA]) and lab values are consistent with cirrhosis
  • Has a history of ≤5 years prior to providing documented except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or cutaneous Kaposi's sarcoma
  • Has a history or current evidence of any condition (including active tuberculosis infection), therapy, laboratory abnormality, or other circumstance (including drug or alcohol use or dependence) that might, in the opinion of the investigator, confound the results of the study or interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
537 participants (actual)

Study arms

  • Experimental
    DOR/ISL

    Participants take DOR/ISL and placebo to BIC/FTC/TAF once daily (qd) for 144 weeks.

    Drug: DOR/ISL · Drug: Placebo to BIC/FTC/TAF

  • Active comparator
    BIC/FTC/TAF

    Participants take BIC/FTC/TAF and placebo to DOR/ISL qd for 144 weeks.

    Drug: BIC/FTC/TAF · Drug: Placebo to DOR/ISL

Interventions

  • DrugDOR/ISL

    Drug pages: Doravirine · Islatravir

    Fixed dose combination tablet containing DOR/ISL 100 mg/0.25 mg taken by mouth.

    Also known as: MK-8591A

  • DrugBIC/FTC/TAF

    Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide

    Fixed dose combination tablet containing BIC/FTC/TAF 50 mg/200 mg/25 mg taken by mouth.

  • DrugPlacebo to DOR/ISL

    Placebo tablet matched to DOR/ISL tablet taken by mouth.

  • DrugPlacebo to BIC/FTC/TAF

    Placebo tablet matched to BIC/FTC/TAF tablet taken by mouth.

06

What researchers measure

Primary outcomes

  1. Percentage of participants with human immunodeficiency virus type 1 (HIV-1) ribonucleic acid (RNA) <50 copies/mL at Week 48

    Plasma HIV-1 RNA quantification will be performed at the central laboratory using a polymerase chain reaction (PCR) assay with a lower limit of detection of \<50 copies/mL.

    Time frame: Week 48

  2. Percentage of participants experiencing ≥1 adverse event (AE) through Week 48

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 48 weeks

  3. Percentage of participants discontinuing from study treatment due to an AE through Week 48

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 48 weeks

Secondary outcomes

  1. Percentage of participants with HIV-1 RNA <50 copies/mL at Week 96

    Plasma HIV-1 RNA quantification will be performed at the central laboratory using a PCR assay with a lower limit of detection of \<50 copies/mL.

    Time frame: Week 96

  2. Percentage of participants with HIV-1 RNA <50 copies/mL at Week 144

    Plasma HIV-1 RNA quantification will be performed at the central laboratory using a PCR assay with a lower limit of detection of \<50 copies/mL.

    Time frame: Week 144

  3. Percentage of participants with HIV-1 RNA <200 copies/mL at Week 48

    Plasma HIV-1 RNA quantification will be performed at the central laboratory using a PCR assay with a lower limit of detection of \<50 copies/mL.

    Time frame: Week 48

  4. Percentage of participants with HIV-1 RNA <200 copies/mL at Week 96

    Plasma HIV-1 RNA quantification will be performed at the central laboratory using a PCR assay with a lower limit of detection of \<50 copies/mL.

    Time frame: Week 96

  5. Percentage of participants with HIV-1 RNA <200 copies/mL at Week 144

    Plasma HIV-1 RNA quantification will be performed at the central laboratory using a PCR assay with a lower limit of detection of \<50 copies/mL.

    Time frame: Week 144

  6. Change from baseline in cluster of differentiation 4+ (CD4+) T-cells at Week 48

    CD4+ T-cells are quantified with a T and B lymphocyte and natural killer cell (TBNK) panel.

    Time frame: Baseline (Day 1) and Week 48

  7. Change from baseline in CD4+ T-cells at Week 96

    CD4+ T-cells are quantified with a TBNK panel.

    Time frame: Baseline (Day 1) and Week 96

  8. Change from baseline in CD4+ T-cells at Week 144

    CD4+ T-cells are quantified with a TBNK panel.

    Time frame: Baseline (Day 1) and Week 144

  9. Incidence of viral drug resistance

    Plasma samples will be collected for genotypic and phenotypic HIV-1 viral drug resistance testing and used to assess resistance-associated substitutions and viral susceptibility as applicable during the study.

    Time frame: Up to 96 weeks

  10. Change from baseline in body weight at Week 48

    Body weight will be collected throughout the study.

    Time frame: Baseline (Day 1) and Week 48

  11. Change from baseline in body weight at Week 96

    Body weight will be collected throughout the study.

    Time frame: Baseline (Day 1) and Week 96

  12. Change from baseline in body weight at Week 144

    Body weight will be collected throughout the study.

    Time frame: Baseline (Day 1) and Week 144

  13. Percentage of participants experiencing ≥1 AE through Week 144

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 144 weeks

  14. Percentage of participants discontinuing from study treatment due to an AE through Week 144

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 144 weeks

07

Study locations

131 sites

Showing the first 100 of 131 sites across 21 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Rockstroh JK, Kassim S, Paredes R, Bettacchi C, Sinclair G, Avihingsanon A, Mugo N, Molina JM, Crabtree Ramirez B, Gatanaga H, Xu Y, Klopfer SO, Diamond TL, Vesnesky M, Stamm LM, Fox MC, Pisculli ML. Fixed-dose daily doravirine (100 mg) with islatravir (0.25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial. Lancet HIV. 2026 Jul;13(7):e440-e451. doi: 10.1016/S2352-3018(26)00033-0. Epub 2026 Feb 25. PubMed 41763226 ↗

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Oct 2025, 31 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2023
First posted
Jan 30, 2023
StartActual
Mar 8, 2023
Primary completionActual
Oct 13, 2025
CompletionEst.
Aug 5, 2029
Results delay requested
Sep 22, 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, registry dates and references
1 update, last Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Minor edits only
    + 3 other changes: verification date, registry dates and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05705349
Responsible party
Sponsor
First posted
Jan 30, 2023
Start date
Mar 8, 2023
Primary completion
Oct 13, 2025
Completion
Aug 5, 2029 (estimated)
Last update
Oct 5, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Doravirine · Islatravir

Start the discussion